A focused review on the use of botulinum toxins for neuropathic pain

Clinical Journal of Pain

Volumn 18, Issue 6 SUPPL., 2002, Pages

  Argoff, Charles E ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Analgesics; Botulinum toxins; Neuropathic pain; Nociceptive pain

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ANALGESIA; ANALGESIC ACTIVITY; CENTRAL NERVOUS SYSTEM; CHEMICAL INJURY; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME; DIABETIC NEUROPATHY; DRUG EFFECT; DRUG EFFICACY; HUMAN; MECHANICS; MYOFASCIAL PAIN; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE RECEPTOR; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; REVIEW; SPINAL CORD INJURY; SYMPTOM; THERMAL INJURY; TISSUE INJURY;

BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; BRACHIAL PLEXUS NEUROPATHIES; CLINICAL TRIALS; HERPES ZOSTER; HUMANS; MYOFASCIAL PAIN SYNDROMES; NERVOUS SYSTEM DISEASES; NEURALGIA; PAIN; POLYNEUROPATHIES; REFLEX SYMPATHETIC DYSTROPHY; SPINAL CORD INJURIES; TREATMENT OUTCOME;

EID: 0036840028     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002508-200211001-00010     Document Type: Review

References (22)

1. Bennett GJ. Neuropathic pain: New insights, new interventions. Hosp Pract 1998;33:95-8.
2. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001:107-10.
3. Gunn CC. Neuropathic myofascial pain syndromes. In: Loeser JD, Butler SH, Chapman CR, et al., eds. Bonica's Management of Pain. Philadelphia: Lippincott Williams & Wilkins, 2001:522-9.
4. Costigan M, Woolf CJ. Pain molecular mechanisms. J Pain 2000;1(suppl 3):35-44.
5. Woolf CP, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 1992:355:75-8.
6. Woolf CP, Doubell TP. The pathophysiology of chronic pain increased sensitivity to low threshold A beta-fiber inputs. Curr Opin Neurobiol 1994;4:525-34.
7. Bennett GJ. Update on the neurophysiology of pain transmission and modulation: Focus on the NMDA-receptor. J Pain Sympt Manag 2000;19(1 suppl):S2-6.
8. Allen G, Galer BS, Schwartz L. Epidemiology of complex regional pain syndrome: A retrospective chart review of 134 patients. Pain 199;80:539-44.
9. Simons DG, Travell JG, Simons LS. General overviews. In: Simons DG, Travell JG, Simons LS, Travell & Simons' Myofascial Pain and Dysfunction: The Trigger Point Manual. Vol. 1. 2nd Ed. Baltimore: Williams & Wilkins, 1999:11-93.
10. Hubbard DR, Berkoff GM. Myofascial trigger points show spontaneous needle EMG activity. Spine 1993;18:1803-7.
11. Ali Z, Ringkamp M, Hartke TV, et al. Uninjured C-fiber nociceptors develop spontaneous activity and alpha-adrenergic sensitivity following L6 spinal nerve ligation in monkey. J Neurophysiol 1999;81:455-66.
12. Ali Z, Raja SN, Wesselmann U, et al. Intradermal injection of norepinephrine evokes pain in patients with sympathetically maintained pain. Pain 2000;88:161-8.
13. Argoff CE. Botulinum toxin type A treatment of myofascial pain in patients with CRPS Type 1 (reflex sympathetic dystrophy): A pilot study. Poster Presentation at the World Pain Congress (IASP) Meeting, Vienna, Austria, August 1999.
14. Harden RN, Bruehl S, Galer BS. Complex regional pain syndrome: Are the IASP diagnostic criteria valid and sufficiently comprehensive? Pain 1999;83:211-9.
15. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: The neuropathic pain scale. Neurology 1997;48:332-8.
16. Galer BS. Personal Communication, 1999.
17. Jabbari B, Maher N. Effectiveness of botulinum toxin A against the segmental burning pain of spinal cord origin. Poster Presentation at the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Hannover, Germany, June 8-12, 2002.
18. Freund B, Schwartz M. Subcutaneous BTX-A in the treatment of neuropathic pain: A pilot study. Presented at the 38th Interagency Botulism Research Coordinating Committee Meeting, October 1719, 2001, Easton, MD.
19. Kamen LB. Botulinum toxin type B (Myobloc™) for treatment of neuromuscular pain associated with brachial plexopathy. Poster presentation at the Annual Scientific Meeting of the American Pain Society, Baltimore. MD, March 2001.
20. Vernon H, Mior S. The Neck Disability Index: A study of reliability and validity. J Manipulative Phys Ther 1991;14:409-15.
21. McMahon HT, Foran P, Dolly JO, et al. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. J Biol Chem 1992;267:21338-43.
22. Cui ML, Khanijou S, Rubino J, et al. Botulinum toxin A inhibits the inflammatory pain in the rat formalin model. Soc Neurosci 2000;26:656 (abstract).